CTIS2023-508411-23-00进行中（未招募）1 期
PREDIX HER2 - Neoadjuvant response-guided treatment of HER2 positivebreast cancer. Part of a platform of translational phase II trials based onmolecular subtypes
Karolinska University Hospital0 个研究点目标入组 200 人开始时间: 2023年9月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Written informed consent, Patients with breast cancer confirmed by histology, characterized by immunohistochemistry for ER, PR, HER2 and proliferation marker, Tumor and blood samples available. HER2 type confirmed by genomic profiling using Next-Generation Sequencing., Age 18 years or older. Elderly patients in condition adequate for planned therapy, Primary breast cancer >20mm in diameter and/or verified lymph node metastases, Adequate bone marrow, renal, hepatic and cardiac functions and no other uncontrolled medical or psychiatric disorders, LVEF >55%, ECOG performance status 0-1, Primary breast cancer as defined in p. 5 plus at most 2 morphologically characterized well-defined distant metastases accessible for stereotactic radiotherapy, provided that this treatment is available.
排除标准
- •Distant metastases, including node metastases in the contralateral thoracic region or in the mediastinum, Other malignancy diagnosed within the last five years, except for radically treated basal or squamous cell carcinoma of the skin or CIS of the cervix, Patients in child-bearing age without adequate contraception, Pregnancy or lactation, Uncontrolled hypertension, heart, liver, kidney related or other medical or psychiatric disorders.
研究者
相似试验
进行中（未招募）
1 期
PREDIX HER2 - preoperative treatment of HER2 positive breast cancerEUCTR2014-000808-10-SEKarolinska University Hospital200
招募中
3 期
Optimizing neoadjuvant systemic treatment in HER2 positive breast cancer - the TRAIN-2 studyHER2 positive breast cancer10006291breast cancerNL-OMON45049BOOG Study Center (onderzoeksgroep zonder winstoogmerk)430
进行中（未招募）
不适用
Optimizing neoadjuvant systemic treatment in HER2 positive breast cancer - the TRAIN-2 studyBreast cancer, HER2 positive, stage II or IIIMedDRA version: 18.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10006200Term: Breast cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10006201Term: Breast cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-001863-21-NLBOOG Study Center
招募中
不适用
A Phase II trial of preoperative HER2 targeting and endocrine therapy in postmenopausal women with HER2 and HR positive breast cancerNeoplasmsKCT0001583Yonsei University Health System, Gangnam Severance Hospital132
招募中
1 期
eoadjuvant Chemotherapy for HER2-positive Stage IV advanced gastric cancer with S-1/Cisplatin/TrastuzumabGastric CancerJPRN-UMIN000005548The University of Tokyo Hospital6